berotralstat structure biocryst molecules of the year drug hunter

oral plasma kallikrein serine protease inhibitor

approved for prevention of HAE attacks

from structure-based drug design

berotralstat

BioCryst, Birmingham, AL

The Biocryst oral plasma kallikrein inhibitor, berotralstat (BCX7353), was recently approved as the first non-steroidal treatment for prevention of hereditary angioedema attacks. The molecule is given orally (150 mg…


     this content is exclusive to
    Premium members

    Unlock this content with a Premium membership to read it now.